Authors: Christiain Ottensmeier, (University of Southampton, UK)
Initial results from the Phase III CheckMate -227 study have been announced. The pivotal study has demonstrated that the combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) can significantly extend progression-free survival (PFS) in those with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumours have high tumour mutation burden (TMB). In this interview with CheckMate -227 trial investigator, Christian Ottensmeier (University of Southampton, UK), we explore the trial in more detail and see where the field is heading.
Could you give us a brief overview of the CheckMate -227 study?